Literature DB >> 1919423

Cost-benefit analysis of non-pharmacological treatment of hypertension.

M Johannesson1, H Aberg, L Agréus, L Borgquist, B Jönsson.   

Abstract

In this study a non-pharmacological treatment (NPT) programme and conventional drug treatment of hypertension was compared in a cost-benefit analysis. The NPT programme involved 400 patients and was conducted at 8 health centres during the period 1984-1986. It consisted of monthly visits by a nurse, visits by a doctor every 6 months, home blood pressure (BP) measurements, dietary advice, relaxation, physical activity, etc. The patients were also followed up for 2 years after the study to assess whether the programme still worked, and whether future treatment costs were affected. The treatment costs were about SEK 5300 higher per patient for the NPT programme. The benefits, in the form of reduced treatment costs for the period 1986-1988 and willingness to pay (WTP) for the NPT programme, were about SEK 3200. Thus the NPT programme resulted in a loss of about SEK 2100 per patient. However, a longer follow-up period is needed for any specific conclusions to be drawn about the costs and benefits of the NPT programme, as compared with conventional drug treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1919423     DOI: 10.1111/j.1365-2796.1991.tb00449.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  8 in total

1.  Unexpected yes- and no-answering behaviour in the discrete choice approach to elicit willingness to pay: a methodological comparison with payment cards.

Authors:  Thomas Hammerschmidt; Hans-Peter Zeitler; Reiner Leidl
Journal:  Int J Health Care Finance Econ       Date:  2003-09

2.  The Australian Guidelines for subsidisation of pharmaceuticals: the road to cost-effective drug prescribing?

Authors:  M Johannesson
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

3.  Economic evaluation of drug therapy: a review of the contingent valuation method.

Authors:  M Johannesson; P O Johansson; B Jönsson
Journal:  Pharmacoeconomics       Date:  1992-05       Impact factor: 4.981

4.  Assessing community values in health care: is the 'willingness to pay' method feasible?

Authors:  C Donaldson; S Farrar; T Mapp; A Walker; S Macphee
Journal:  Health Care Anal       Date:  1997-03

5.  A review of cost-effectiveness analyses of hypertension treatment.

Authors:  M Johannesson; B Jönsson
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

Review 6.  Defining the patient group for cost-effective withdrawal of antihypertensive therapy.

Authors:  L R Krakoff; S Wassertheil-Smoller
Journal:  Pharmacoeconomics       Date:  1995-03       Impact factor: 4.981

Review 7.  Economics of Self-Measured Blood Pressure Monitoring: A Community Guide Systematic Review.

Authors:  Verughese Jacob; Sajal K Chattopadhyay; Krista K Proia; David P Hopkins; Jeffrey Reynolds; Anilkrishna B Thota; Christopher D Jones; Daniel T Lackland; Kimberly J Rask; Nicolaas P Pronk; John M Clymer; Ron Z Goetzel
Journal:  Am J Prev Med       Date:  2017-08-14       Impact factor: 5.043

8.  Economic aspects of hypertension treatment in Poland.

Authors:  Jana Krzysztoszek; Dorota Koligat; Piotr Ratajczak; Wiesław Bryl; Maciej Cymerys; Karolina Hoffmann; Ewelina Wierzejska; Paweł Kleka
Journal:  Arch Med Sci       Date:  2013-01-21       Impact factor: 3.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.